Xenon Pharmaceuticals XENE Stock-Based Comp
Stock-Based Comp at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ShareBasedCompensation.
The official record: Xenon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's stock-based comp.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's stock-based comp?
- Xenon Pharmaceuticals (XENE) reported stock-based comp of $16.89M in Q1 2026.
- How has Xenon Pharmaceuticals's stock-based comp changed year-over-year?
- Xenon Pharmaceuticals's stock-based comp increased by 38.8% year-over-year, from $12.17M to $16.89M.
- What is the long-term trend for Xenon Pharmaceuticals's stock-based comp?
- Over 4 years (2021 to 2025), Xenon Pharmaceuticals's stock-based comp has grown at a 52.2% compound annual growth rate (CAGR), from $10.02M to $53.71M.
- What does stock-based comp mean?
- Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.